CAJ | 학술논문

目的：探讨单药同步放化疗治疗大肠癌的临床疗效和不良反应。方法将2004年至2013年间我院收治的80例大肠癌患者随机分为实验组（50例）和对照组（30例）。实验组患者采用单药同步放化疗方案治疗，对照组采用单药化疗方案治疗，观察和比较两组患者的临床疗效、疼痛缓解情况、血清IL-2和IL-10水平及不良反应。结果治疗后，实验组和对照组的总有效率分别为90.00％和70.00％，实验组显著高于对照组（P<0.05）；实验组患者的疼痛改善率显著高于对照组（90.00％ vs.66.67％，P<0.05）；两组治疗后的血清IL-2水平均显著高于治疗前（P<0.05），而血清IL-10水平均明显低于治疗前（P<0.05），且实验组治疗后血清IL-2水平显著高于对照组（P<0.05）；两组患者的不良反应发生率比较，差异无统计学意义。结论单药同步放化疗治疗大肠癌较单药化疗更有效，能更显著地改善患者的疼痛和免疫功能，不良反应可耐受，值得临床推广应用。
목적：탐토단약동보방화료치료대장암적림상료효화불량반응。방법장2004년지2013년간아원수치적80례대장암환자수궤분위실험조（50례）화대조조（30례）。실험조환자채용단약동보방화료방안치료，대조조채용단약화료방안치료，관찰화비교량조환자적림상료효、동통완해정황、혈청IL-2화IL-10수평급불량반응。결과치료후，실험조화대조조적총유효솔분별위90.00％화70.00％，실험조현저고우대조조（P<0.05）；실험조환자적동통개선솔현저고우대조조（90.00％ vs.66.67％，P<0.05）；량조치료후적혈청IL-2수평균현저고우치료전（P<0.05），이혈청IL-10수평균명현저우치료전（P<0.05），차실험조치료후혈청IL-2수평현저고우대조조（P<0.05）；량조환자적불량반응발생솔비교，차이무통계학의의。결론단약동보방화료치료대장암교단약화료경유효，능경현저지개선환자적동통화면역공능，불량반응가내수，치득림상추엄응용。
Objective To investigate the efficacy and adverse reactions of single-agent concurrent chemoradiotherapy for colorectal cancer. Methods Eighty colorectal cancer patients treated in our hospital between January 2004 and Decem-ber 2013 were divided into experiment group (n=50) and control group (n=30) by random number table. The experiment group was treated with single-agent concurrent chemoradiotherapy, while the control group was treated with single chemo-therapy. The clinical efficacy, pain relief rates and serum IL-2/IL-10 levels of the two groups were observed and compared. Results After the treatment, the total effective rate of the experimental group (90%) was significantly higher than that of the control group (70%, P<0.05). The pain relief rate of the experimental group (90%) was significantly higher than that of the control group (66.67%, P>0.05). After treatment, the serum IL-2 levels of the two groups were averagely higher than before treatment, while the serum IL-10 levels were averagely lower than before treatment (P<0.05). In addition, the serum IL-2 level of the experimental group was significantly higher than that of the control group (P<0.05). There were no significant differences in incidence of adverse reactions between the two groups. Conclusion Single-agent concurrent chemoradio-therapy for colorectal cancer was more effective than single-agent chemotherapy. It has better pain relief rate and better protection of the patient's immune function, and its adverse reactions could be tolerated. It is worthy of clinical application.